The FDA enforcement report dated 14 October lists several Class II recalls of compounded incretin products. They include semaglutide syringes, semaglutide and tirzepatide combined with cyanocobalamin, and a tirzepatide multi-dose vial. The reason given in each is lack of assurance of sterility; for most, the firm attributes this to formulation with bacteriostatic water and to processing equipment.
Class II means use could cause temporary or medically reversible harm, or that serious harm is unlikely. It is a manufacturing finding, not a report of infections. The recalls are ongoing.
Compounded semaglutide and tirzepatide grew during shortages and are often marketed directly to consumers, sometimes with vitamins added. The practical step is to ask. A patient who reports using one can be moved to an approved product where available, and checked for local or systemic signs of infection.
- The recalls name compounded semaglutide and tirzepatide syringes and vials, some mixed with cyanocobalamin.
- The stated reason is lack of assurance of sterility, linked to formulation and processing equipment.
- Two US compounders are named: Carolina Infusion and Apothecary Pharma.
- Ask about injection-site redness, swelling or fever in anyone using a compounded product.
- These are US products; whether any reached India is unknown.
Why it matters
Compounded incretin products carry manufacturing risks that branded pens do not, and patients rarely volunteer the source of their injections.
Don't overread it
A Class II recall reflects a possible manufacturing problem; it does not establish that any patient was harmed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free